Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects
Early analysis and remedy of rheumatoid arthritis (RA) are of crucial significance to halt the development of the illness. Optimum use of superior imaging methods or biomarkers could facilitate early analysis of RA. Though many disease-modifying anti-rheumatic medicine (DMARDs) can be found for RA remedy, organic DMARDs (bDMARDs) provide increasing therapeutic choices and good outcomes in sufferers with RA who would not have a enough response to traditional artificial DMARDs.
Nonetheless, excessive prices of bDMARDs have restricted affected person entry to optimised illness administration and elevated the associated fee burden for healthcare methods. The appearance of biosimilars led to important value financial savings pushed by worth competitors among the many reference merchandise, which might be useful for healthcare methods.
Healthcare supplier (HCP)-patient communication and knowledgeable shared decision-making are essential to forestall the incidence of a nocebo impact, which ends up from unfavorable perceptions that sufferers could have and will result in much less efficient outcomes. Analysis has demonstrated that efficient communication between HCPs and sufferers utilising constructive framing can enhance acceptance by sufferers to be initiated on or switched to a biosimilar and will help to combine biosimilars into routine scientific apply to maximise advantages for sufferers with RA.
circ-PTTG1IP/miR-671-5p/TLR4 axis regulates proliferation, migration, invasion and inflammatory response of fibroblast-like synoviocytes in rheumatoid arthritis
Round RNAs (circRNAs) are associated to rheumatoid arthritis (RA) growth. Nonetheless, the operate and mechanism of circRNA pituitary tumor-transforming 1 interacting protein (circ- PTTG1IP) in RA are unknown. The expression of circ-PTTG1IP in synovial tissues of RA sufferers and fibroblast-like synoviocytes from RA sufferers (RA-FLSs) have been detected by RT-qPCR. The outcomes uncovered that circ-PTTG1IP was overexpressed in RA sufferers and RA-FLSs, and circ-PTTG1IP knockdown suppressed cell proliferation, migration, invasion and inflammatory response in RA-FLSs.
Apart from, we discovered that circ-PTTG1IP may straight bind to miR-671-5p, and toll-like receptor 4 (TLR4) was a goal of miR-671-5p, which was confirmed by dual-luciferase reporter assay. miR-671-5p inhibitor attenuated the consequences of circ-PTTG1IP knockdown on RA-FLSs, whereas the consequences of miR-671-5p mimic on RA-FLSs have been partly reversed by TLR4 overexpression. Moreover, circ-PTTG1IP may upregulate TLR4 expression by miR-671-5p. Thus, circ-PTTG1IP knockdown repressed cell proliferation, migration, invasion and inflammatory response in RA-FLSs by regulating the miR-671-5p/TLR4 axis.
[Severe Hepatitis E virus infection in a patient with rheumatoid arthritis treated with baricitinib]
A affected person with rheumatoid arthritis (RA) was introduced, who developed an an infection with the hepatitis E virus (HEV) below remedy with the Janus kinase (JAK) 1 and a pair of inhibitor baricitinib. Within the 3‑month routine check-up the affected person had clearly elevated transaminase ranges with an not easily seen bodily examination. The investigations detected antibodies of IgM and IgG courses in opposition to HEV and an elevated C‑reactive protein (CRP) degree in addition to HEV-RNA by real-time PCR, which is indicative of a latest HEV an infection.

Baricitinib was instantly discontinued. The intensive anamnesis revealed that the affected person had eaten beef tartar some days earlier than the session, with out the incidence of gastrointestinal signs or fever. Within the additional course the affected person utterly recovered and the liver operate exams and the CRP ranges normalized inside Three months. Baricitinib was then restarted. Up to now solely few studies have been printed on HEV infections in RA sufferers who’ve been handled with JAK inhibitors.
Nanomedicines for the remedy of rheumatoid arthritis: State of artwork and potential therapeutic methods
Rising understanding of the pathogenesis of rheumatoid arthritis (RA) has remarkably promoted the event of efficient therapeutic regimens of RA. However, the insufficient response to present therapies in a proportion of sufferers, the systemic toxicity accompanied by long-term administration or distribution in non-targeted websites and the comprised efficacy attributable to undesirable bioavailability, are nonetheless unsettled issues mendacity throughout the complete remission of RA.
Up to now, these current limitations have impressed complete tutorial researches on nanomedicines for RA remedy. Quite a lot of versatile nanocarriers with controllable physicochemical properties, tailorable drug launch sample or lively focusing on capability have been fabricated to reinforce the drug supply effectivity in RA remedy. This evaluate goals to offer an up-to-date progress relating to to RA remedy utilizing nanomedicines within the final 5 years and concisely talk about the potential software of a number of newly emerged therapeutic methods resembling inducing the antigen-specific tolerance, pro-resolving remedy or regulating the immunometabolism for RA therapies.
Hypertension and dyslipidemia are threat components for herpes zoster in sufferers with rheumatoid arthritis: a retrospective evaluation utilizing a medical info database
This research used knowledge from a large-scale multicenter medical info database in Japan to estimate the incidence fee of herpes zoster (HZ) and to look at the connection between hypertension, dyslipidemia, and diabetes mellitus (DM), and the chance of HZ amongst sufferers with rheumatoid arthritis (RA). The analysis dataset consisted of 221,196 information of potential goal sufferers with RA extracted between April 1, 2008 and August 31, 2017 from the Medical Information Imaginative and prescient database. To evaluate the affiliation between hypertension, dyslipidemia, and DM and the chance of HZ, a case-control research was arrange. Data of 101,498 research topics met the inclusion standards.
H2B Antibody Antibody |
AF4659 |
Affbiotech |
200ul |
EUR 376 |
Description: H2B Antibody Antibody detects endogenous levels of H2B. |
anti- Antibody^Polyclonal antibody control antibody |
LSMab09882 |
Lifescience Market |
100 ug |
EUR 438 |
Anti-Anti-SEPT5 Antibody antibody |
STJ25477 |
St John's Laboratory |
100 µl |
EUR 277 |
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced. |
Anti-Anti-SEPT8 Antibody antibody |
STJ25479 |
St John's Laboratory |
100 µl |
EUR 277 |
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
Anti-Anti-SEPT7 Antibody antibody |
STJ28963 |
St John's Laboratory |
100 µl |
EUR 277 |
Description: This gene encodes a protein that is highly similar to the CDC10 protein of Saccharomyces cerevisiae. The protein also shares similarity with Diff 6 of Drosophila and with H5 of mouse. Each of these similar proteins, including the yeast CDC10, contains a GTP-binding motif. The yeast CDC10 protein is a structural component of the 10 nm filament which lies inside the cytoplasmic membrane and is essential for cytokinesis. This human protein functions in gliomagenesis and in the suppression of glioma cell growth, and it is required for the association of centromere-associated protein E with the kinetochore. Alternative splicing results in multiple transcript variants. Several related pseudogenes have been identified on chromosomes 5, 7, 9, 10, 11, 14, 17 and 19. |
Anti-Anti-SEPT8 Antibody antibody |
STJ117206 |
St John's Laboratory |
100 µl |
EUR 277 |
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
Anti-Anti-SEPT12 Antibody antibody |
STJ117759 |
St John's Laboratory |
100 µl |
EUR 277 |
Description: This gene encodes a guanine-nucleotide binding protein and member of the septin family of cytoskeletal GTPases. Septins play important roles in cytokinesis, exocytosis, embryonic development, and membrane dynamics. Multiple transcript variants encoding different isoforms have been found for this gene. |
Anti-Anti-SEPT1 antibody antibody |
STJ119580 |
St John's Laboratory |
100 µl |
EUR 277 |
Description: This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis and the maintenance of cellular morphology. This gene encodes a protein that can form homo- and heterooligomeric filaments, and may contribute to the formation of neurofibrillary tangles in Alzheimer's disease. Alternatively spliced transcript variants have been found but the full-length nature of these variants has not been determined. [provided by RefSeq, Dec 2012] |
Anti-Anti-SEPT7 Antibody antibody |
STJ116214 |
St John's Laboratory |
100 µl |
EUR 277 |
Description: This gene encodes a protein that is highly similar to the CDC10 protein of Saccharomyces cerevisiae. The protein also shares similarity with Diff 6 of Drosophila and with H5 of mouse. Each of these similar proteins, including the yeast CDC10, contains a GTP-binding motif. The yeast CDC10 protein is a structural component of the 10 nm filament which lies inside the cytoplasmic membrane and is essential for cytokinesis. This human protein functions in gliomagenesis and in the suppression of glioma cell growth, and it is required for the association of centromere-associated protein E with the kinetochore. Alternative splicing results in multiple transcript variants. Several related pseudogenes have been identified on chromosomes 5, 7, 9, 10, 11, 14, 17 and 19. |
Anti-Anti-SEPT6 antibody antibody |
STJ11100949 |
St John's Laboratory |
100 µl |
EUR 277 |
Description: This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis. One version of pediatric acute myeloid leukemia is the result of a reciprocal translocation between chromosomes 11 and X, with the breakpoint associated with the genes encoding the mixed-lineage leukemia and septin 2 proteins. This gene encodes four transcript variants encoding three distinct isoforms. An additional transcript variant has been identified, but its biological validity has not been determined. |
Anti-Anti-SEPT9 Antibody antibody |
STJ111369 |
St John's Laboratory |
100 µl |
EUR 277 |
Description: This gene is a member of the septin family involved in cytokinesis and cell cycle control. This gene is a candidate for the ovarian tumor suppressor gene. Mutations in this gene cause hereditary neuralgic amyotrophy, also known as neuritis with brachial predilection. A chromosomal translocation involving this gene on chromosome 17 and the MLL gene on chromosome 11 results in acute myelomonocytic leukemia. Multiple alternatively spliced transcript variants encoding different isoforms have been described. |
Anti-Anti-SEPT4 Antibody antibody |
STJ112276 |
St John's Laboratory |
100 µl |
EUR 277 |
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is highly expressed in brain and heart. Alternatively spliced transcript variants encoding different isoforms have been described for this gene. One of the isoforms (known as ARTS) is distinct; it is localized to the mitochondria, and has a role in apoptosis and cancer. |
Anti-Anti-SEPT5 Antibody antibody |
STJ114819 |
St John's Laboratory |
100 µl |
EUR 277 |
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced. |
Ly1 Antibody Reactive (LYAR) Antibody |
20-abx123734 |
Abbexa |
|
|
|
Anti-Glycoprotein Antibody (GP) Antibody |
20-abx319900 |
Abbexa |
-
EUR 411.00
-
EUR 1845.00
-
EUR 599.00
-
EUR 182.00
-
EUR 300.00
|
-
100 ug
-
1 mg
-
200 ug
-
20 ug
-
50 ug
|
|
Anti-Glycoprotein Antibody (GP) Antibody |
20-abx319901 |
Abbexa |
-
EUR 411.00
-
EUR 1845.00
-
EUR 599.00
-
EUR 182.00
-
EUR 300.00
|
-
100 ug
-
1 mg
-
200 ug
-
20 ug
-
50 ug
|
|
Anti-Glycoprotein Antibody (GP) Antibody |
20-abx319905 |
Abbexa |
-
EUR 411.00
-
EUR 1845.00
-
EUR 599.00
-
EUR 182.00
-
EUR 300.00
|
-
100 ug
-
1 mg
-
200 ug
-
20 ug
-
50 ug
|
|
Anti-Glycoprotein Antibody (GP) Antibody |
20-abx319913 |
Abbexa |
-
EUR 411.00
-
EUR 1845.00
-
EUR 599.00
-
EUR 182.00
-
EUR 300.00
|
-
100 ug
-
1 mg
-
200 ug
-
20 ug
-
50 ug
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
20-abx311665 |
Abbexa |
-
EUR 411.00
-
EUR 1845.00
-
EUR 599.00
-
EUR 182.00
-
EUR 300.00
|
-
100 ug
-
1 mg
-
200 ug
-
20 ug
-
50 ug
|
|
Anti-Glycolipid Antibody (AGA) Antibody |
20-abx004855 |
Abbexa |
-
EUR 411.00
-
EUR 592.00
-
EUR 182.00
-
EUR 314.00
|
-
100 ul
-
200 ul
-
20 ul
-
50 ul
|
|
Anti-Glycolipid Antibody (AGA) Antibody |
abx036399-100ug |
Abbexa |
100 ug |
EUR 391 |
|
Ly1 Antibody Reactive (LYAR) Antibody |
20-abx008109 |
Abbexa |
-
EUR 300.00
-
EUR 439.00
-
EUR 189.00
|
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
20-abx014333 |
Abbexa |
-
EUR 314.00
-
EUR 98.00
-
EUR 398.00
-
EUR 495.00
|
-
100 ug
-
10 ug
-
200 ug
-
300 µg
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
abx033330-400ul |
Abbexa |
400 ul |
EUR 523 |
|
Ly1 Antibody Reactive (LYAR) Antibody |
abx033330-80l |
Abbexa |
80 µl |
EUR 286 |
|
Ly1 Antibody Reactive (LYAR) Antibody |
abx234901-100ug |
Abbexa |
100 ug |
EUR 551 |
|
Anti-Glycolipid Antibody (AGA) Antibody |
abx230204-100ug |
Abbexa |
100 ug |
EUR 481 |
|
Ly1 Antibody Reactive (LYAR) Antibody |
20-abx324434 |
Abbexa |
|
|
|
Monoclonal NGF/proNGF Neutralizing Antibody Antibody |
AMM06679G |
Leading Biology |
0.05mg |
EUR 528 |
Description: A Monoclonal antibody against Human NGF/proNGF Neutralizing. The antibodies are raised in Mouse. This antibody is applicable in E |
Anti CD22 Antibody: CD22 Monoclonal Antibody |
065-A-01mg |
Virogen |
0,1 mg |
EUR 267.5 |
|
Description: anti-CD22 monoclonal antibody |
Anti CD22 Antibody: CD22 Monoclonal Antibody |
065-A-1000ug |
Virogen |
1000 ug |
EUR 1282.5 |
|
Description: anti-CD22 monoclonal antibody |
Antibody for Human alpha Tubulin Antibody |
SPC-692D |
Stressmarq |
0.1mg |
EUR 354 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is unconjugated. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-A390 |
Stressmarq |
0.1mg |
EUR 401 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 390. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-A488 |
Stressmarq |
0.1mg |
EUR 400 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 488. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-A565 |
Stressmarq |
0.1mg |
EUR 400 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 565. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-A594 |
Stressmarq |
0.1mg |
EUR 400 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 594. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-A633 |
Stressmarq |
0.1mg |
EUR 400 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 633. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-A655 |
Stressmarq |
0.1mg |
EUR 400 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 655. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-A680 |
Stressmarq |
0.1mg |
EUR 400 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 680. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-A700 |
Stressmarq |
0.1mg |
EUR 400 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to ATTO 700. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-ALP |
Stressmarq |
0.1mg |
EUR 394 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Alkaline Phosphatase. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-APC |
Stressmarq |
0.1mg |
EUR 399 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to APC . |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-APCCY7 |
Stressmarq |
0.1mg |
EUR 471 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to APC/Cy7. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-BI |
Stressmarq |
0.1mg |
EUR 396 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Biotin. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-DY350 |
Stressmarq |
0.1mg |
EUR 414 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 350. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-DY405 |
Stressmarq |
0.1mg |
EUR 403 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 405. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-DY488 |
Stressmarq |
0.1mg |
EUR 393 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 488. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-DY594 |
Stressmarq |
0.1mg |
EUR 395 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 594. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-DY633 |
Stressmarq |
0.1mg |
EUR 390 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Dylight 633. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-FITC |
Stressmarq |
0.1mg |
EUR 392 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to FITC. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-HRP |
Stressmarq |
0.1mg |
EUR 388 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to HRP. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-P594 |
Stressmarq |
0.1mg |
EUR 407 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to PE/ATTO 594. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-PCP |
Stressmarq |
0.1mg |
EUR 399 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to PerCP. |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-RPE |
Stressmarq |
0.1mg |
EUR 397 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to RPE . |
Antibody for Human alpha Tubulin Antibody |
SPC-692D-STR |
Stressmarq |
0.1mg |
EUR 398 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is conjugated to Streptavidin. |
Antibody for Human alpha Tubulin Antibody |
SPC-692S |
Stressmarq |
0.012mg |
EUR 65 |
Description: A polyclonal antibody for alpha Tubulin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide of Human alpha-Tubulin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This alpha Tubulin antibody is unconjugated. |
Anti-Glycoprotein Antibody (GP) Antibody (HRP) |
20-abx319902 |
Abbexa |
-
EUR 411.00
-
EUR 1845.00
-
EUR 599.00
-
EUR 182.00
-
EUR 300.00
|
-
100 ug
-
1 mg
-
200 ug
-
20 ug
-
50 ug
|
|
Anti-Glycoprotein Antibody (GP) Antibody (FITC) |
20-abx319903 |
Abbexa |
-
EUR 411.00
-
EUR 1845.00
-
EUR 599.00
-
EUR 182.00
-
EUR 300.00
|
-
100 ug
-
1 mg
-
200 ug
-
20 ug
-
50 ug
|
|
Anti-Glycoprotein Antibody (GP) Antibody (Biotin) |
20-abx319904 |
Abbexa |
-
EUR 411.00
-
EUR 1845.00
-
EUR 599.00
-
EUR 182.00
-
EUR 300.00
|
-
100 ug
-
1 mg
-
200 ug
-
20 ug
-
50 ug
|
|
Anti-Glycoprotein Antibody (GP) Antibody (HRP) |
20-abx319906 |
Abbexa |
-
EUR 411.00
-
EUR 1845.00
-
EUR 599.00
-
EUR 182.00
-
EUR 300.00
|
-
100 ug
-
1 mg
-
200 ug
-
20 ug
-
50 ug
|
|
Anti-Glycoprotein Antibody (GP) Antibody (FITC) |
20-abx319907 |
Abbexa |
-
EUR 411.00
-
EUR 1845.00
-
EUR 599.00
-
EUR 182.00
-
EUR 300.00
|
-
100 ug
-
1 mg
-
200 ug
-
20 ug
-
50 ug
|
|
Anti-Glycoprotein Antibody (GP) Antibody (Biotin) |
20-abx319908 |
Abbexa |
-
EUR 411.00
-
EUR 1845.00
-
EUR 599.00
-
EUR 182.00
-
EUR 300.00
|
-
100 ug
-
1 mg
-
200 ug
-
20 ug
-
50 ug
|
|
Anti-Glycoprotein Antibody (GP) Antibody (HRP) |
20-abx319914 |
Abbexa |
-
EUR 411.00
-
EUR 1845.00
-
EUR 599.00
-
EUR 182.00
-
EUR 300.00
|
-
100 ug
-
1 mg
-
200 ug
-
20 ug
-
50 ug
|
|
Anti-Glycoprotein Antibody (GP) Antibody (FITC) |
20-abx319915 |
Abbexa |
-
EUR 411.00
-
EUR 1845.00
-
EUR 599.00
-
EUR 182.00
-
EUR 300.00
|
-
100 ug
-
1 mg
-
200 ug
-
20 ug
-
50 ug
|
|
Anti-Glycoprotein Antibody (GP) Antibody (Biotin) |
20-abx319916 |
Abbexa |
-
EUR 411.00
-
EUR 1845.00
-
EUR 599.00
-
EUR 182.00
-
EUR 300.00
|
-
100 ug
-
1 mg
-
200 ug
-
20 ug
-
50 ug
|
|
Anti-Glycoprotein Antibody (GP) Antibody (HRP) |
20-abx319929 |
Abbexa |
-
EUR 411.00
-
EUR 1845.00
-
EUR 599.00
-
EUR 182.00
-
EUR 300.00
|
-
100 ug
-
1 mg
-
200 ug
-
20 ug
-
50 ug
|
|
Anti-Glycoprotein Antibody (GP) Antibody (FITC) |
20-abx319930 |
Abbexa |
-
EUR 411.00
-
EUR 1845.00
-
EUR 599.00
-
EUR 182.00
-
EUR 300.00
|
-
100 ug
-
1 mg
-
200 ug
-
20 ug
-
50 ug
|
|
Anti-Glycoprotein Antibody (GP) Antibody (Biotin) |
20-abx319931 |
Abbexa |
-
EUR 411.00
-
EUR 1845.00
-
EUR 599.00
-
EUR 182.00
-
EUR 300.00
|
-
100 ug
-
1 mg
-
200 ug
-
20 ug
-
50 ug
|
|
Ly1 Antibody Reactive (LYAR) Antibody (HRP) |
20-abx311666 |
Abbexa |
-
EUR 411.00
-
EUR 1845.00
-
EUR 599.00
-
EUR 182.00
-
EUR 300.00
|
-
100 ug
-
1 mg
-
200 ug
-
20 ug
-
50 ug
|
|
Ly1 Antibody Reactive (LYAR) Antibody (FITC) |
20-abx311667 |
Abbexa |
-
EUR 411.00
-
EUR 1845.00
-
EUR 599.00
-
EUR 182.00
-
EUR 300.00
|
-
100 ug
-
1 mg
-
200 ug
-
20 ug
-
50 ug
|
|
Ly1 Antibody Reactive (LYAR) Antibody (Biotin) |
20-abx311668 |
Abbexa |
-
EUR 411.00
-
EUR 1845.00
-
EUR 599.00
-
EUR 182.00
-
EUR 300.00
|
-
100 ug
-
1 mg
-
200 ug
-
20 ug
-
50 ug
|
|
Ly1 Antibody Reactive Homolog (LYAR) Antibody |
20-abx103034 |
Abbexa |
-
EUR 453.00
-
EUR 133.00
-
EUR 1302.00
-
EUR 620.00
-
EUR 342.00
|
-
100 ug
-
10 ug
-
1 mg
-
200 ug
-
50 ug
|
|
Ly1 Antibody Reactive Homolog (LYAR) Antibody |
20-abx103035 |
Abbexa |
-
EUR 467.00
-
EUR 133.00
-
EUR 1344.00
-
EUR 634.00
-
EUR 342.00
|
-
100 ug
-
10 ug
-
1 mg
-
200 ug
-
50 ug
|
|
Ly1 Antibody Reactive Homolog (LYAR) Antibody |
20-abx103036 |
Abbexa |
-
EUR 481.00
-
EUR 133.00
-
EUR 1414.00
-
EUR 662.00
-
EUR 356.00
|
-
100 ug
-
10 ug
-
1 mg
-
200 ug
-
50 ug
|
|
Throughout the remark interval, 2566 sufferers developed HZ and the general incidence fee was 5.2 (95% confidence interval: 5.0-5.Four per 1000 patient-years). Hypertension, dyslipidemia, and DM have been considerably related to an elevated threat of HZ after adjustment for intercourse, age, hospital measurement, and use of anti-rheumatic medicine. When mutual adjustment was made for hypertension, dyslipidemia, and DM, the constructive associations between hypertension and dyslipidemia and the chance of HZ remained important; nevertheless, the constructive affiliation with DM utterly disappeared. RA sufferers with hypertension or dyslipidemia could also be at increased threat of HZ.